Jan. 4, 2024— by Jill Clendening A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity. Insulin sensitivity is how responsive cells are to insulin, an essential...
Dec. 4, 2023—A comprehensive study that integrates multiple analytic approaches has linked a regulatory gene network and functional defects in insulin-producing pancreatic beta cells to Type 2 diabetes.
Nov. 1, 2023—In the largest study of its kind, researchers at Vanderbilt have identified unexpected alterations in the exocrine tissues of the pancreas that occur in the two major forms of diabetes, and with aging and obesity.
Oct. 17, 2023—A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.
Sep. 12, 2023—The Vanderbilt Prize Discovery Lecture featuring Professor Dame Frances Ashcroft, which was scheduled for Thursday, September 14, has been postponed until the spring of 2024. Details will be shared soon. Check the Discovery Lecture website at https://www.vumc.org/discovery-lecture-series/upcoming-lectures.
Sep. 6, 2023—Vanderbilt researchers have uncovered a potential new way to help curb the rapidly rising worldwide prevalence of metabolic disorders, including obesity and diabetes.
Sep. 6, 2023—Renowned diabetes expert Professor Dame Frances Ashcroft, recipient of the 2023 Vanderbilt Prize in Biomedical Science, will deliver her Vanderbilt Prize Discovery Lecture at 4 p.m. Thursday, Sept. 14, in 208 Light Hall.
Aug. 2, 2023—Researchers at Vanderbilt University Medical Center have received a four-year, $28 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to study the relationship between COVID-19 and diabetes.
Aug. 2, 2023—Griffin Rodgers, MD, director of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, described the urgency of the nation’s diabetes epidemic July 26 during a symposium of the NIDDK Medical Student Research Program in Diabetes and Obesity hosted by Vanderbilt University.
Jun. 14, 2023—Ideas for addressing the disproportionate impact of cancer, diabetes, and gastrointestinal diseases on disadvantaged populations were shared recently during a diversity symposium at Vanderbilt University Medical Center.
May. 8, 2023—Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.